AustCancer cheered by survival study
09 February, 2005 by Renate KrelleAustralian Cancer Technology has reaped quick rewards and impressed shareholders with a drug it licensed in September last year, which has doubled the survival rate of patient with pancreatic cancer in a Phase I/II study conducted in Germany.
Solbec completes Phase I psoriasis trial
09 February, 2005 by Melissa TrudingerSolbec Pharmaceuticals (ASX: SBP) has announced successful completion of its Phase I study of its devil's apple-derived drug Coramsine as a treatment for psoriasis.
FDA gives Ventracor trial conditional approval
08 February, 2005 by Melissa TrudingerVentracor (ASX: VCR) has received conditional approval from the US FDA for a feasibility study leading up to a full scale trial of its cardiac assist device as a bridge-to-transplant.
Chemgenex drug shows stamina
08 February, 2005 by Melissa TrudingerChemgenex (ASX: CXS) has provided updated results from its Phase I /II clinical study of anti-cancer drug Quinamed at the American Association for Cancer Research's Oncogenomics 2005 conference in the US.
Sassine leaves Visiomed
07 February, 2005 by Renate KrelleWA biotech Visiomed (ASX:VSG) has replaced retiring CEO Saliba Sassine with William Dolphin, formerly of New Zealand's SpectraNet and patient monitoring equipment company, SonaMed.
Peptech reaffirms acquisition strategy
07 February, 2005 by Renate KrellePeptech (ASX:PTD) CEO Mel Bridges used today's annual general meeting to reveal that the company is keen to use its AUD$65 million warchest to fund acquisitions.
In brief: ResMed, Meditech, Ventracor
04 February, 2005 by Staff WritersResMed (ASX:RMD) shares were up almost 5 per cent today after the company announced record revenue and income results for the quarter ended December 31 Revenue for the quarter was US$103.9 million, a 26 per cent increase over the same quarter last year. Net income for the quarter was US$17.4 million.
Biotech's in for a good year, says Burrill
04 February, 2005 by Renate KrelleThe Burrill Biotech Select Index slipped 4.6 per cent in January, but Steve Burrill is bullish about 2005, despite the ramifications of the Merck-Vioxx situation spilling over into the biotech sector.
Western Australian GM ban becomes election issue
03 February, 2005 by Graeme O'NeillWestern Australia's moratorium on genetically modified crops has emerged as a potential electoral liability for state premier Geoff Gallop's ALP government, as the state approaches a cliffhanger election.
Progen aims for first-line therapy
02 February, 2005 by Graeme O'NeillBrisbane cancer-drug developer Progen Industries (ASX:PGL, NASDAQ:PGLAF) is planning a new trial of its lead compound PI-88 in patients with metastatic melanoma - this time as an adjuvant therapy to prevent the deadly cancer progressing in newly diagnosed patients.
Norwood Immunology gets IND for bone marrow therapy
02 February, 2005 by Graeme O'NeillMelbourne immune therapy developer Norwood Immunology Ltd (AIM:NIM) has announced that the US Food and Drug Administration has granted investigational new drug (IND) approval for its first bone-marrow transplant trial in cancer patients
Starpharma and Anadis to develop biodefence antibodies
01 February, 2005 by Graeme O'NeillMelbourne biotechs Starpharma (ASX:SPL, USOTC:SPHRY) and Anadis are teaming up to develop a two-pronged defence against biowarfare agents like pneumonic plague and anthrax.
Judge lays out timetable for Biota-GSK stoush
01 February, 2005 by Melissa TrudingerThe timetable for the legal fight between Biota (ASX: BTA) and pharmaceutical giant GlaxoSmithKline (GSK) has been agreed to by the companies' legal teams.
Acrux pushes forward
01 February, 2005 by Melissa TrudingerIn the four months since it listed on the ASX, Melbourne-based Acrux (ASX: ACR) has had a busy time of it. This week the company announced successful completion of its Phase I study for a transdermal spray to deliver pain drug Fentanyl to treat severe chronic pain. CEO Igor Gonda is confident that this outcome gives the company an attractive commercial opportunity.
Ferriscan receives FDA approval
28 January, 2005 by Melissa TrudingerInner Vision Biometrics (IVB), a subsidiary of Perth based Resonance Health (ASX: RHT) has received FDA marketing approval for its novel diagnostic test for liver iron concentrations.
